CA2090321A1 - Therapeutically useful 2-aminotetralin derivatives - Google Patents

Therapeutically useful 2-aminotetralin derivatives

Info

Publication number
CA2090321A1
CA2090321A1 CA002090321A CA2090321A CA2090321A1 CA 2090321 A1 CA2090321 A1 CA 2090321A1 CA 002090321 A CA002090321 A CA 002090321A CA 2090321 A CA2090321 A CA 2090321A CA 2090321 A1 CA2090321 A1 CA 2090321A1
Authority
CA
Canada
Prior art keywords
hydrogen
therapeutically useful
het
cycloalkyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002090321A
Other languages
French (fr)
Other versions
CA2090321C (en
Inventor
Chiu-Hong Lin
Susanne R. Haadsma
Montford F. Piercey
Arthur G. Romero
William H. Darlington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Chiu-Hong Lin
Susanne R. Haadsma
Montford F. Piercey
Arthur G. Romero
William H. Darlington
Upjohn Company (The)
Pharmacia & Upjohn Company
The Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiu-Hong Lin, Susanne R. Haadsma, Montford F. Piercey, Arthur G. Romero, William H. Darlington, Upjohn Company (The), Pharmacia & Upjohn Company, The Upjohn Company filed Critical Chiu-Hong Lin
Publication of CA2090321A1 publication Critical patent/CA2090321A1/en
Application granted granted Critical
Publication of CA2090321C publication Critical patent/CA2090321C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C07C45/57—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
    • C07C45/59—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Abstract

This invention is therapeutically useful 2-aminotetralins and pharmaceutically acceptable acid addition salts thereof of for-mula (I), wherein R is hydrogen or halogen, wherein R1 is hydrogen, OR4, SR4, CONR5R6, CN, het, C(O)het, CF3, SO2NR5R6, 5-oxazolyl, CSNR5R6, OSO2CF3, wherein R2 and R3 are independently hydrogen, alkyl, alkenyl, alkynyl, (CH2)m-cycloalkyl; (CH2)m-cycloalkenyl, (CH2)m-aryl, (CH2)m-CO2R4, (CH2)m-OR4, wherein R4, R5 and R6 are independ-ently hydrogen, alkyl, alkenyl, cycloalkyl, and wherein X is (CH2)n, m = 0-4, n = 4-8, p = 0,1. These compounds are use-ful to treat central nervous system disorders, hypertension, diabetes, sexual impotency and to control appetite.
CA002090321A 1990-10-12 1991-09-26 Therapeutically useful 2-aminotetralin derivatives Expired - Fee Related CA2090321C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US59691690A 1990-10-12 1990-10-12
US596,916 1990-10-12
US59692390A 1990-10-15 1990-10-15
US596,923 1990-10-15
PCT/US1991/006863 WO1992006967A1 (en) 1990-10-12 1991-09-26 Therapeutically useful 2-aminotetralin derivatives

Publications (2)

Publication Number Publication Date
CA2090321A1 true CA2090321A1 (en) 1992-04-13
CA2090321C CA2090321C (en) 2002-04-09

Family

ID=27082677

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002090321A Expired - Fee Related CA2090321C (en) 1990-10-12 1991-09-26 Therapeutically useful 2-aminotetralin derivatives

Country Status (6)

Country Link
EP (1) EP0552246A1 (en)
JP (1) JPH06502165A (en)
KR (1) KR100207876B1 (en)
CA (1) CA2090321C (en)
HU (1) HU211928A9 (en)
WO (1) WO1992006967A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301732D0 (en) * 1993-05-18 1993-05-18 Haakan Wilhelm Wikstroem NEW CENTRALLY ACTING 5-, 6-, 7-, AND 8-SUBSTITUTED SULPHONE ESTERS OF N-MONOSUBSTITUTED 2-AMINOTETRALINS
US5457121A (en) * 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US6844368B1 (en) 1998-12-22 2005-01-18 Edward Roberts Compounds useful in pain management
NZ569608A (en) * 2006-01-06 2011-09-30 Sepracor Inc Tetralone-based monoamine reuptake inhibitors
WO2009121872A2 (en) 2008-04-01 2009-10-08 Abbott Gmbh & Co. Kg Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (en) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES IN THERAPY
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2014001457A (en) 2011-08-05 2014-08-21 Abbvie Deutschland Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquin oline derivatives, pharmaceutical compositions containing them, and their use in therapy.
CA2853254A1 (en) 2011-11-18 2013-05-23 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015055771A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2924689A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2352020A (en) * 1939-11-17 1944-06-20 Scheuing Georg Process for the production of analgetically active tetrahydronaphthols
GB2037288B (en) * 1977-08-04 1982-07-14 Squibb & Sons Inc Naphthalene derivatives
SE8004002L (en) * 1980-05-29 1981-11-30 Arvidsson Folke Lars Erik THERAPEUTICALLY APPLICABLE TETRALIN DERIVATIVES
US4876269A (en) * 1986-09-10 1989-10-24 E. I. Du Pont De Nemours And Company Benoz-fused cycloalkane trans-1,2-diamine derivatives

Also Published As

Publication number Publication date
CA2090321C (en) 2002-04-09
EP0552246A1 (en) 1993-07-28
WO1992006967A1 (en) 1992-04-30
JPH06502165A (en) 1994-03-10
KR100207876B1 (en) 1999-07-15
HU211928A9 (en) 1996-01-29

Similar Documents

Publication Publication Date Title
CA2090321A1 (en) Therapeutically useful 2-aminotetralin derivatives
DK0476016T3 (en) CNS-active 8-heterocyclyl-2-aminotetraline derivatives
FI113651B (en) Process for the preparation of therapeutically useful bentsimidazole compounds
DE122004000039I1 (en) Gaba and L-glutaminase analogues for the treatment of epilepsy
ES8306708A1 (en) Therapeutically useful 1-alkyl-2-aminotetralin derivatives.
US4711958A (en) Morpholine containing amino acid derivatives
MY106401A (en) N-imidazolyl-and-n-imidazolymethyl-derivatives of substituted bicyclic compounds.
DE69030665D1 (en) (1,2N) AND (3,2N) -BOXYCLICAL-2-AMINO-TETRALINE DERIVATIVES
ZA909043B (en) Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders
IT1211792B (en) O-ALCANOIL ACID DERIVATIVES 3 AMINO 2- HYDROXYPROPANSULPHONIC ANTICONVULSIVE ADAPTITY AND THEIR PHARMACEUTICAL COMPOSITIONS FOR THE THERAPEUTIC TREATMENT OF EPILEPSY
EA199700287A1 (en) BENZAMIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
DE69206607T2 (en) TREATMENT OF COGNITIVE DISORDERS.
GR3006432T3 (en)
MY123317A (en) Synthesis of chiral beta-amino acids
FI103970B1 (en) A process for the preparation of 3- (1,2-benzisoxazol-3-yl) -4-pyridinamine and derivatives thereof for the treatment of pain and for the treatment of dermatological and memory disorders
FI904184A0 (en) Analogous Process for the Preparation of Therapeutically Useful Oxodibenzoxepine and Oxothienobenzoxepinalkylamine and Alkanoic Acid Amide Derivatives
EP0575500A1 (en) Hiv protease inhibitors
ES8704922A2 (en) Improvements to the subject matter of patent of invention no. 541,911 relating to Process for obtaining new [alpha]- (alkylaminopropionyl)-thiophen derivatives substituted in the thiophen ring

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed